Synthesis, and biological evaluation of EGFR/HER2-NAMPT conjugates for tumor treatment-Reference-Cited by-同舟云学术

Synthesis, and biological evaluation of EGFR/HER2-NAMPT conjugates for tumor treatment

Published:2023-07-23 Issue: Volume: Page:
ISSN:1381-1991
Container-title:Molecular Diversity
language:en
Short-container-title:Mol Divers

Author:

Ding Mengyuan,Shen Qianqian,Lu Wei,Zhu Shulei

Publisher

Springer Science and Business Media LLC

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Drug Discovery,Molecular Biology,General Medicine,Information Systems,Catalysis

Link

https://link.springer.com/content/pdf/10.1007/s11030-023-10701-y.pdf

Reference57 articles.

1. Jaracz S, Chen J, Kuznetsova LV, Ojima I (2005) Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem 13(17):5043–5054

2. Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T, Mardaneh J, Farhadihosseinabadi B, Larki P, Faghfourian B, Sepehr KS, Abbaszadeh-Goudarzi K, Abbaszadeh-Goudarzi G, Johari B, Zali MR, Bagheri N (2019) Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes. J Cell Physiol 234(5):5628–5642

3. Baker JH, Lindquist KE, Huxham LA, Kyle AH, Sy JT, Minchinton AI (2008) Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res 14(7):2171–2179

4. Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, Burris Iii HA, LoRusso PM, Yi JH, Saad O, Tong B, Chu YW, Holden S, Joshi A (2012) Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 69(5):1229–1240

5. Perino S, Moreau B, Freda J, Cirello A, White BH, Quinn JM, Kriksciukaite K, Someshwar A, Romagnoli J, Robinson M, Movassaghian S, Cipriani T, Wooster R, Bilodeau MT, Whalen KA (2020) Novel miniaturized drug conjugate leverages HSP90-driven tumor accumulation to overcome PI3K inhibitor delivery challenges to solid tumors. Mol Cancer Ther 19(8):1613–1622

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual-targeted NAMPT inhibitors as a progressive strategy for cancer therapy;Bioorganic Chemistry;2024-08

2. Design, synthesis and inhibitory activity against Candida albicans of a series of derivatives with 5-nitrofuran scaffold;Molecular Diversity;2024-05-30